EP1304952A2 - Implantable analyte sensor - Google PatentsImplantable analyte sensor
- Publication number
- EP1304952A2 EP1304952A2 EP20010933715 EP01933715A EP1304952A2 EP 1304952 A2 EP1304952 A2 EP 1304952A2 EP 20010933715 EP20010933715 EP 20010933715 EP 01933715 A EP01933715 A EP 01933715A EP 1304952 A2 EP1304952 A2 EP 1304952A2
- European Patent Office
- Prior art keywords
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Detecting, measuring or recording for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1486—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase
- A61B5/14865—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/001—Enzyme electrodes
- C12Q1/005—Enzyme electrodes involving specific analytes or enzymes
- C12Q1/006—Enzyme electrodes involving specific analytes or enzymes for glucose
Implantable Analyte Sensor
The present invention relates to implantable analyte sensors.
Several implantable glucose sensors have been developed. Examples include those described in U.S. Patent numbers 5,387,327, 5,41 1 ,647; and 5,476,776; as well as those described in PCT International Publication numbers WO 91/15993; WO 94/20602; WO 96/06947; and WO 97/19344 The implantable glucose sensors usually include a polymer substrate, with metal electrodes printed on the surface of the substrate. A biocompatible membrane covers the electrodes, allowing glucose to reach the electrodes, while excluding other molecules, such as proteins. Electrochemistry, often with the aid of enzymes at the electrodes, is used to determine the quantity of glucose present The glucose sensor is implanted into a patient, and the elec- trodes may be attached via wires that pass out of the patient's body to external circuitry that controls the electrodes, measures and reports the glucose concentration. Alternatively, all or part of this external circuitry may be miniaturized and included in the implantable glucose sensor. A transmitter, such as that described in WO 97/19344, may even be included in the implantable glucose sensor, completely eliminating the need for leads that pass out of the patient.
A problem associated with an amperometπc glucose sensor is unstable signals. This may result from degradation of the en/vme from interaction with protein, leakage of the enzyme, and/or fouling of the electrode The usual way to overcome this is to use the above described biocompatible membrane, or a coating However, several problems are also associated with these membranes. For example, Nafion-based biosensor membranes exhibit cracking, flaking, pro¬ tein adhesion, and calcium deposits. Mineralization of polymer-based membranes occurs in the biological environment, resulting in cracking and changes in permeability. The tortuous porosity associated with polymer membranes has also been shown to be important in mem¬ brane stability and mineralization in vivo Biological components, which enter pores or voids in the material, cause metabolic shadows, which are loci for ion and calcium accumulation. This situation, coupled with the fact that mineral deposits have been known to propagate surface fractures in polymeric membranes, presents a potentially serious problem for implantable glucose sensors.
In polymer membranes the pore size distribution usually follows some kind of probability distribution (e.g. gaussian), which leaves a finite probability for large proteins to eventually transfer through the membrane Drift may be caused by this leakage or inadequate diffusion properties, and events at the body-sensor interface such as biofouhng and protein adsorption, encapsulation with fibrotic tissue, and degradation of the device material over time.
Currently, membranes with nominal pore sizes as small as 20 nm are available. Even so, the filtration at these dimensions is far from absolute. The most common filters are polymeric membranes formed from a solvent-casting process, which result in a pore size distribution with variations as large as 30% The use of ion-track etching to form membranes (e.g. MILLPORE ISOPORE) produces a much tighter pore size distribution (±10%) However, these membranes have low porosities (< 109 pores/cm ), limited pore sizes, and the pores are randomly distributed across the surface. Porous alumina (e.g. WHATMAN) has also been used to achieve uniform pores. Although the aluminas typically have higher pore densities (MO1 /cm2), only certain pore sizes (typically greater than 20 nanometers) can be achieved and the pore configurations and arrangements are difficult to control.
In one aspect, the present invention is an implantable analyte sensor, comprising a substrate, electrodes on the substrate, and a membrane on the electrodes. The membrane comprises elemental silicon.
In another aspect, the present invention relates to a method of making an implantable analyte sensor, comprising covering electrodes with a membrane. The electrodes are on a substrate, and the membrane comprises elemental silicon.
The invention also relates to implantable analyte sensors that exhibit a signal drift of less than
BRIEF DESCRIPTION OF THE DRAWINGS
The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein
Figures 1-9 illustrate the process of making a membrane for use in an embodiment of the present invention,
Figure 10 shows a cut-away view of an implantable analyte sensor,
Figure 11 shows an exploded view of an implantable analyte sensor; and Figure 12 shows a cut-awav view of an implatable analyte sensor
Figure 10 shows a cut aw av view of an embodiment of the present invention In the figure, an implantable analyte sensor 2 includes a substrate 6 on which are electrodes 8 and 8 The electrodes are covered with a membrane 4 Leads 12 and 12 allow for electrically connecting the implantable analyte sensor to external circuitry (not shown) The implantable analyte sensor also includes an external coating 16 and an internal coating 14
Figure 11 shows an exploded view of an embodiment of the present invention The internal and external coatings are not included in the figure for clarity As shown in the figure, the implantable analyte sensor 2 includes the electrodes 8 and 8 on the substrate 6 surface, which are electrically connected w ith microelectronic circuitry 10. The microelectronic circuitry is electrically connected to leads 12 and 12, which allow for electrically connecting the implantable analyte sensor to external circuitry (not shown) The electrodes are covered with the membrane 4
Figure 12 shows a cut away view of an embodiment of the present invention similar to that shown in Figure 10, except for the presence of a third electrode 8 and a third lead 12 Although so illustrated, the number of electrodes may be different from the number of leads.
The membrane is composed of a hard material that has been micromachined Preferably, the membrane comprises elemental silicon, but other hard, biocompatable materials that can be micromachined are possible, such as metals (for example titanium), ceramics (for example, silica or silicon nitride), and polymers (such as polvtetrafluoroethylene, polymethyl- methacrvlate, polystyrenes and sihcones) Micromachimng is a process that includes photo¬ lithography, such as that used in the semiconductor industry, to remove material from, or add material too, a substrate These techniques are well known, and are described, in Encyclopedia of Chemical Technology, Kirk-Othmer, Volume 14, pp 677-709 ( 1995), Semiconductor Device Fundamentals, Robert F Pterret, Addison-Weslev, 1996, and Microchip Fabrication 3rd edition, Peter Van Zant, McGraw-Hill, 1997 A detailed fabrication method for a membrane comprising elemental silicon is described in the dissertation of Derek James Hansford, submitted in partial satisfaction of the requirements for the degree of Doctor of Philosophy in Engineering-Materials Science and Mineral Engineering in the Graduate Division of the University of California, Berkeley, submitted in the spring of 1999
A special property of the membrane is a defined pore size, which has a small size distribution compared to the size distribution of standard membranes Due to tight tolerances in the manufacturing process, the pore si/e can be controlled at precise diameters, for example 1 to 50 nm, or 5 to 20 nm, or even 5 to 15 nm (such as 12 nm, 18 nm or even 25 nm), with a variation of +/- 0 01-20%, +/-0 1 10% or even -r7- l-5% Therefore molecules above this size can be excluded with high certainty, since the size distribution has the shape of a top hat, rather than a bell curve, and hence pore sizes above, for example 12 nm, 18 nm, 25 nm or 50 nm are not present These membranes can exclude interfering molecules, such as proteins, which could otherwise cause major drift problems of the sensor, when the sensor is implanted in vivo Signal drift is a change in the magnitude of the signal from a sensor which is unrelated to changes in analyte concentration The amount of signal drift is based on the magnitude of the signal prior to the drifting Preferably, the implantable analyte sensors of the present invention exhibit a signal drift of less than 20% per day in vivo, more preferably less than 10% per day in vivo, most preferably less than 5% per day in vivo
Membranes for use in the present invention may be characterized by a glucose diffusion test and an albumin diffusion test These tests are described below Preferably, the membrane has a glucose diffusion test result of at least 1 mg/dl in 330 min , more preferably at least 10 mg/dl in 330 min , even more preferably at least 30 mg/dl in 330 min , and most preferably at least 60 mg/dl in 330 min Preferably, the membrane has an albumin diffusion test result of at most 0 1 g/dl in 420 min , more preferably at most 0 05 g/dl in 420 min , even more preferably at most 0 01 g/dl in 420 min , and most preferably at most 0 001 g/dl in 420 min
The manufacturing process of the membranes may allow a simple and economical production of small, implantable analyte sensors For example, the membranes can be first manufactured, and then on a substrate, the electrodes for the sensor and the electrical connectors can be formed Preferably, the substrate is silicon, but other materials are possible, such as ceramics, or polymers If desired, electronic components, for example amplifiers, filters, transmitters and/or signal preconditioning components, can easily be incorporated in this layer. In particular, if the substrate comprises elemental silicon, well known integrated circuit technology may be used to place all the circuitry in miniaturized form on a single chip.
There are two possible approaches to attach the substrate and the membrane, when a reagent is included in the sensor:
1. The substrate and the membrane are thermally bonded before the reagent is deposited on the electrodes. In this case, an opening, preferably in the membrane is provided (since this may be manufactured with a micromachining process, an opening is easily generated during one of the processing steps). In the case where multiple membranes are formed as a single piece, and or multiple substrates are formed as a single piece, after thermal bonding, a further etching step may be used to separate the individual membrane/ substrate units. The reagent is deposited through the individual openings and the openings are sealed using, for example a polymer sealant. The individual sensors are then separated, incorporated into a flexible, inner coating, for example silicone rubber, and indi- vidually coated with an outer coating, such as a biocompatible layer.
2. The reagent is deposited on the electrodes before the membrane and substrate are attached. In this case, thermal bonding is not possible, since the enzyme in the reagent would be destroyed. The individual membranes and substrates are first separated and the individual sensors are assembled by bonding one membrane with one substrate using a suitable bonding agent, for example, cyanoacrylate. As a final step, the individual sensors are incorporated into a flexible, inner coating, for example silicone rubber, and individually coated with an outer coating, such as a biocompatible layer. The sensor can be inserted into the skin using a needle applicator. The control unit typically remains outside the body and can be connected to the sensor element through electrical wires (leads).
The electrodes are formed on the surface of the substrate. They may be formed by well known semiconductor processing techniques, from conductive materials, such as pure metals or alloys, or other materials which are metallic conductors. Examples include aluminum, carbon (such as graphite), cobalt, copper, gallium, gold, indium, iridium, iron, lead, magnesium, mercury (as an amalgam), nickel, niobium, osmium, palladium, platinum, rhenium, rhodium, selenium, silicon (such as highly doped polycrystalline silicon), silver, tantalum, tin, titanium, tungsten, uranium, vanadium, zinc, zirconium, mixtures thereof, and alloys or metallic com¬ pounds of these elements. Preferably, the electrodes include gold, platinum, palladium, iridium, or alloys of these metals, since such noble metals and their alloys are unreactive in biological systems The electrodes may be any thickness, but preferably are 10 nm to 1 mm, more preferably, 20 nm to 100 μm, or even 25 nm to 1 μm
At least two electrodes must be present The number of electrodes may be 2- 1000, or 3-200, or even 3-99 Individual electrode sets (2 or 3 electrodes) may be separated into individual chambers, each covered with the membrane Furthermore, individual electrode sets (2 or 3 electrodes) may each have a different reagent, allowing for an implantable analvte sensor that can measure at least two, such as 3-100, or 4-20, different analytes
The remaining individual part of the implantable analyte sensors are well known to those of ordinary skill in the art, and are described, for example, in U S Patent numbers 5,387,327; 5,411,647, and 5,476,776, as well as in PCT International Publication numbers WO 91/15993; WO 94/20602, WO 96/06947, and WO 97/19344
Although illustrated with both leads and microelectronic circuitry, these components are optional. The microelectronic circuitry may include some or all of the electrical components normally external to the implantable analyte sensor, such as a microprocessor, an amplifier, or a power supply If the microelectronic circuitry also includes a transmitter, or another device for sending information wirelessly, such as a laser which emits light through the skin, then there is no need to include the leads Alternatively, the microelectronic circuitry may not be present, in which case the lead will directly electrically connect the electrodes with external electrical components
Optionally, one or more internal coatings may be present The internal coating may function to regulate diffusion Examples of internal coatings include cellulose acetate, polyurethanes, polyallylamines (PAL), polyaziπdine (PAZ), and silicon-containing polymers Some specific examples are described in PCT Publications WO 98/17995, WO 98/13685 and WO 96/06947, and in U S Patent Nos 4,650,547 and 5,165,407
Optionally, one or more external coatings may be present The implantable analvte sensors of the present invention are intended to be used in vivo, preferably subcutaneouslv in mammals, such as humans, dogs or mice The external coatings function to improve the biocompatibility of the implantable analyte sensor Examples of external coatings include nafion, polyure¬ thanes, polytetrafluoroethvlenes (PTFE), poly (ethylene oxide) (PEO), and 2 methacryloy- loxyethyl phosphorylchohne-co-n-butyl methacrylate (MPC) membranes Some specific examples are described in PCT Publication WO 96/06947, and in ' Medical Progress through Technology , Nishida et al 21 91 103 ( 1995) The electrodes may be coated with a reagent. The reagent is optional, and mav be used to provide electrochemical probes for specific analytes. The reagent may be as simple as a single enzyme, such as glucose oxidase or glucose hydrogenase for the detection of glucose. The enzyme may be immobilized or "wired" as described in PCT Publication WO 96/06947. The reagents may optionally also include a mediator, to enhance sensitivity of the sensor. The starting reagents are the reactants or components of the reagent, and are often compounded together in liquid form before application to the electrodes. The liquid may then evaporate, leaving the reagent in solid form. The choice of specific reagent depends on the specific analyte or analytes to be measured, and are well known to those of ordinary skill in the art. For exam- pie, a reagent for measurement of glucose can contain 62.2 mg polyethylene oxide (mean molecular weight of 100-900 kilodaltons), 3.3 mg NATROSOL 250 M, 41.5 mg AVICEL RC- 591 F, 89.4 mg monobasic potassium phosphate, 157.9 mg dibasic potassium phosphate, 437.3 mg potassium ferπcyanide, 46 0 mg sodium succinate, 148.0 mg trehalose, 2.6 mg TRITON X- 100 surfactant, and 2,000 to 9,000 units of enzyme activity per gram of reagent. The enzyme is prepared as an enzyme solution from 12.5 mg coenzyme PQQ and 1.21 million units of the apoenzyme of quinoprotein glucose dehvdrogenase, forming a solution of quinoprotein glucose dehydrogenase. This reagent is described in WO 99/30152, pages 7-10, hereby incorporated by referece.
Other non-limiting examples of enzymes and optional mediators that may be used in meas- uπng particular analvtes in the present invention are listed below in Table 1.
Analyte Enzymes Mediator Additional Mediator (Oxidized Form)
Glucose Glucose DehydrogeFerricyanide nase and Diaphorase Glucose Glucose-Dehydroge- Ferricyanide nase
Cholesterol (Quinoprotein) Ferricyanide 2,6-Dimethyl-l,4- Cholesterol Esterase Benzoquinone and Cholesterol 2,5-Dichloro-l,4-Benzo- Oxidase quinone or Phenazine Ethosulfate
HDL Cholesterol Cholesterol Esterase Ferricyanide 2,6-Dιmethyl- l,4-Benzo- and Cholesterol quinone Oxidase
2,5-Dichloro- l,4-Benzo- quinone or Phenazine Ethosulfate
Triglyceπdes Lipoprotein Lipase, Ferricyanide or Phenazine Methosulfate Glycerol Kinase, and Phenazine Glycerol-3-Phosphate Ethosulfate Oxidase
Lactate Lactate Oxidase Ferricyanide 2,6-Dichloro- l,4-Benzo- quinone
Lactate Lactate DehydrogeFerricyanide nase and Diaphorase Phenazine Ethosulfate, or Phenazine Methosulfate
Lactate Diaphorase Ferricyamde Phenazine Ethosulfate, or Dehydrogenase Phenazine Methosulfate
Pyruvate Pyruvate Oxidase Ferricyanide
Alcohol Alcohol Oxidase Phenylenediamine
Bilirubin Bilirubin Oxidase 1-Methoxy- Phenazine
Uric Acid Uncase Ferricyanide In some of the examples shown in Table 1, at least one additional enzyme is used as a reaction catalyst Also, some of the examples shown in Table 1 may utilize an additional mediator, which facilitates electron transfer to the oxidized form of the mediator The additional mediator may be provided to the reagent in lesser amount than the oxidized form of the mediator While the above assays are described, it is appreciated that a variety of electrochemical assays may be conducted in accordance with this disclosure
Formation of membrane
The following describes how to make a membrane for use in the present invention, based on the description from the dissertation of Derek James Hansford, submitted in partial satis- faction of the requirements for the degree of Doctor of Philosophy in Engineering-Materials Science and Mineral Engineering in the Graduate Division of the University of California, Berkeley, submitted in the spring of 1999
Other membranes, made from other material, may also be used This specific method relies upon a buried nitride etch stop layer
The buried nitride etch stop layer acts as an etchant stop during the formation of nanometer scale pores The buried nitride etch stop layer facilitates three-dimensional control of the pore structure, and facilitates the formation of pores less than 50 nanometers in diameter Moreover, these pores can be uniformly formed across the entire wafer
Preferabh , the first step in the fabrication protocol is to etch a support ridge structure into a substrate The ridges provide mechanical rigidity to the subsequently formed membrane structure
A low stress silicon nitride (LSN or nitride), which operates as an etch stop layer, is then deposited on the substrate using low pressure chemical vapor depositions (LPCVD) In one embodiment, 0 4 μm of nitride was used The resultant structure is shown in Figure 1 Figure 1 illustrates a substrate 20 with a nitride etch stop layer 22 formed thereon
The base structural layer (base layer) of the membrane is deposited on top of the stop layer 22 Since the etch stop layer 22 is thin, the structural layer is deposited down into the support ridges formed in the substrate 20 In one embodiment, 5 μm of polysihcon is used as the base layer Figure 2 illustrates the base layer 24 positioned on the etch stop layer 22 Low stress silicon nitride may also be used as the base layer, in which case it operates as its own etch stop layer The next processing step is to etch holes in the base layer 24 to define the shape of the pores Masks, such as those used in traditional semiconductor processing, may be used to define the pores For example, the holes may be etched through the polysi con by chlorine plasma, with a thermally grown oxide layer used as a mask In this step, it is important to make sure the etching goes completely through the base layer 24, so a 10-15% overetch is preferably used. It is useful to note that the buried nitride etch stop 22 acts as an etch stop for the plasma etching of a silicon base layer 24 Otherwise, if the plasma punched through the nitride, tighter control of the etch step would have to be exercised to prevent the complete removal of the nitride under the plug layer (to prevent removal in the final KOH etch) Figure 3 illustrates the result of this processing In particular, the figure illustrates holes 26 formed in the base layer 24, but terminating in the nitride etch stop laver 22
Pore sacrificial oxide is subsequently grown on the base layer 24 Figure 4 illustrates a sacrificial oxide 28 positioned on the base laver 24
The sacrificial oxide thickness determines the pore size in the final membrane, so control of this step is critical to reproducible membranes This is accomplished by the thermal oxidation of the base layer 24 (e g , a growth temperature of between 850-950°C for approximately one hour with a ten minute anneal) Naturally, many techniques may be used to form a controlled thickness sacrificial layer For example, a thermally evaporated tungsten film may be used as a sacrificial layer for polymer membranes and selectively removed with hydrogen peroxide The basic requirement of the sacrificial laver is the ability to control the thickness with high precision across the entire wafer Thermal oxidation of both polysihcon and nitride allows the control of the sacrificial layer thickness of less than 5% across the entire wafer Limitations on this control arise from local inhomogeneities in the base layer, such as the initial thickness of the native oxide (especially for polysihcon) the grain size or the density, and the impurity con- centrations
To mechanically connect the base layer 24 with the plug layer (necessary to maintain the pore spacing between layers), anchor points were defined in the sacrificial oxide layer 26 In the present design, this is accomplished bv using the same mask shifted from the pore holes by 1 μm diagonally This produced anchors in one or two corners of each pore hole, which pro- vides the desired mechanical connection between the structural layers while opening the pore area as much as possible Figure 5 illustrates anchors 30 formed via this process A plug structural layer is subsequently deposited to fill in the holes 26. This step has been implemented by depositing 1.5 μm of polysihcon. The resultant plug layer 32 is shown in Figure 6.
To open the pores at the surface, the plug layer 32 is planarized down to the base layer, leaving the final structure with the plug layer only in the pore hole openings, as shown in Figure 7.
The method of planarization depends on the material used as the plug material. For the hard micro-fabrication materials (polysihcon and nitride), chemical mechanical polishing was used for planarization. The other materials studied were roughly planarized using a plasma etch, with a quick wet chemical smoothing. This technique has the advantage that, assuming it is not etched by the plasma used, the base layer is not affected, but has the disadvantage of the need for controlled etch timing to avoid completely etching the plugs themselves.
At this point, the membrane is ready for release, so a protective layer 34 is deposited on the wafer (completely covering both sides of the wafer). The requirements of the protective layer 34 are that it be impervious to the silicon etch (KOH for these studies) and that it be removed without removing the plug 32 or base 24 structural layers. For polysihcon and nitride structural layers, a thin nitride layer is used as the protective layer (nitride is not etched at all by KOH and dissolves slowly in HF). For polymeric structural materials, silicon is used as a protective layer, due to the processing temperature necessary for nitride deposition (835° C).
The backside etch windows were etched in the protective layer, exposing the silicon in desired areas, and then the entire structure was placed in an 80°C KOH bath until the silicon wafer substrate 20 is etched up to the membrane base layer 24 (as evidenced by the smooth buried etch stop layer). Figure 8 illustrates the resultant aperture 36 formed in the substrate 20.
At this point, the buried nitride layer 22, the sacrificial oxide layer 34, and plug layer 32 are removed by etching in HF or SF6/oxygen plasma. The resultant membrane 4 with nanometer scale pores is shown in Figure 9.
Characterization of membranes
The purpose of the membranes is to allow the analyte of interest (such as glucose) to diffuse through the membrane, while excluding large molecules (such as proteins). Therefore, two important characteristics of the membranes are glucose diffusion and albumin diffusion. All tests are carried out at room temperature (25°C). The following is a glucose diffusion test:
Diffusion of glucose is measured using a mini diffusion chamber constructed around the membranes. The diffusion chamber, fabricated out of acrylic, consists of two compartments A and B with fixed volumes of 2 ml, separated by the desired membrane, sealed with o-rings, and screwed together.
Glucose is measured on either side of the membrane using the diffusion chamber by means of a quantitative enzymatic assay (TRINDER™, SIGMA) and colorometπc reading via a spec- trophotometer. Starting glucose concentrations for all tests were 6,666 mg/dl and 0.0 mg/dl in chambers A and B, respectively. Samples of 0.1 ml are taken from the diffusion chamber and 10 μl of that are added to 3 ml of glucose reagent in a cuvette, and mixed gently by inversion. Each tube is incubated for 18 minutes at room temperature and then readings are taken at a wavelength of 505 nm. The reagent is linear up to 750 mg/dl. The diffusion chamber itself is attached to a motor for stirring in order to minimize boundary layer effects (diffusion resis¬ tance at the liquid/membrane interface). In order to ensure wetting of the pores, the receptor cell is first filled with phosphate buffer saline (PBS) for fifteen minutes before the filling of the donor cell. The donor cell is filled with solutions of glucose in PBS in varying concentrations.
The following is an albumin diffusion test:
Albumin is also measured on either side of the membrane using the same diffusion chamber as in the glucose diffusion test Albumin diffusion and/or exclusion is first measured and quantified using Albumin BCP (bromocresol purple, SIGMA). Starting albumin concentrations for all tests are 4 g/dl and 0.0 mg/dl in chambers A and B, respectively. A sample of 0.1 ml is taken at time zero and at the end of the diffusion period (time = 330 minutes). An aliquot of 300 μl is then added to 3 ml of the reagent and absorbence is read at 600 nm. Reagent plus deiomzed water is used as the blank. The BCP assay is linear up to 6g/dl but is not accurate below 1 g/dl. For the small concentration of albumin that might be present in chamber A, the presence of any protein in chamber B is measured using the Bradford Method (MICRO PROTEIN KIT, SIGMA). This method quantitates the binding of Coomassie bril¬ liant blue to an unknown protein and compares this binding to that of different amounts of a standard protein. Albumin is used as a standard protein. This method quantifies 1 to 100 micrograms protein using a standard curve, with sensitivity down to 10 mg/dl or 0.1 g/dl protein. The absorbance is measured at 595 nm. Analysis of membranes
Diffusion of glucose was measured for three types of membranes: silicon micromachined membranes (average pore size = 0.0245 microns), WHATMAN ANODISC membranes (average pore size = .02 microns), and MF-MILLIPORE mixed cellulose acetate and nitrate membrane (average pore size = 0.025 microns).
The results from the albumin test are shown in the table below.
The presence of albumin does not seem to impede passage of glucose through the membranes, nor slow down glucose transport. No detectable amounts of albumin diffuse through the micromachined membrane. The same membrane, however, shows glucose diffusion. The micromachined membranes are able to achieve complete exclusion of albumin (to within the limits of detection), while allowing glucose diffusion. Comparing diffusion rates with that of commercially available membranes, the micromachined membranes have glucose diffusion properties comparable to MILLIPORE and alumina WHATMAN membranes with similar pore sizes.
The passage of albumin through the micromachined membrane is measured by looking at the change of albumin concentration in chamber A and chamber B over time. Using the BCP assay, there are no detectable traces of albumin in chamber B. However, the amount of albumin in chamber B may have been below the limits of detectability of this assay system. There- fore, the Bradford Method was also employed. Using this microassay, again no detectable amounts of albumin were found in chamber B for the micromachined membrane, but small amounts of protein were found in chamber B using both the MILLIPORE and WHATMAN membranes. The amounts of albumin detected after 420 minutes in chamber B were approximately 0.25 g/dl and 0.20 g/dl albumin for the MILLIPORE and WHATMAN mem- branes, respectively. Glucose does diffuse through micromachined membranes at a rate comparable to commercially available membranes. At the same time, albumin is excluded from passage. In mixed solutions of glucose and albumin, only glucose diffuses through the micromachined membranes.
Priority Applications (3)
|Application Number||Priority Date||Filing Date||Title|
|PCT/EP2001/003026 WO2001069222A2 (en)||2000-03-17||2001-03-16||Implantable analyte sensor|
|Publication Number||Publication Date|
|EP1304952A2 true EP1304952A2 (en)||2003-05-02|
Family Applications (1)
|Application Number||Title||Priority Date||Filing Date|
|EP20010933715 Withdrawn EP1304952A2 (en)||2000-03-17||2001-03-16||Implantable analyte sensor|
Country Status (5)
|EP (1)||EP1304952A2 (en)|
|JP (1)||JP2003527599A (en)|
|AU (1)||AU6013001A (en)|
|CA (1)||CA2406814A1 (en)|
|WO (1)||WO2001069222A2 (en)|
Families Citing this family (38)
|Publication number||Priority date||Publication date||Assignee||Title|
|US6862465B2 (en)||1997-03-04||2005-03-01||Dexcom, Inc.||Device and method for determining analyte levels|
|US8527026B2 (en)||1997-03-04||2013-09-03||Dexcom, Inc.||Device and method for determining analyte levels|
|US8465425B2 (en)||1998-04-30||2013-06-18||Abbott Diabetes Care Inc.||Analyte monitoring device and methods of use|
|US9066695B2 (en)||1998-04-30||2015-06-30||Abbott Diabetes Care Inc.||Analyte monitoring device and methods of use|
|US8346337B2 (en)||1998-04-30||2013-01-01||Abbott Diabetes Care Inc.||Analyte monitoring device and methods of use|
|US8688188B2 (en)||1998-04-30||2014-04-01||Abbott Diabetes Care Inc.||Analyte monitoring device and methods of use|
|US8974386B2 (en)||1998-04-30||2015-03-10||Abbott Diabetes Care Inc.||Analyte monitoring device and methods of use|
|US6175752B1 (en)||1998-04-30||2001-01-16||Therasense, Inc.||Analyte monitoring device and methods of use|
|US6560471B1 (en)||2001-01-02||2003-05-06||Therasense, Inc.||Analyte monitoring device and methods of use|
|US6702857B2 (en)||2001-07-27||2004-03-09||Dexcom, Inc.||Membrane for use with implantable devices|
|US20030032874A1 (en)||2001-07-27||2003-02-13||Dexcom, Inc.||Sensor head for use with implantable devices|
|US9282925B2 (en)||2002-02-12||2016-03-15||Dexcom, Inc.||Systems and methods for replacing signal artifacts in a glucose sensor data stream|
|US9763609B2 (en)||2003-07-25||2017-09-19||Dexcom, Inc.||Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise|
|US7613491B2 (en)||2002-05-22||2009-11-03||Dexcom, Inc.||Silicone based membranes for use in implantable glucose sensors|
|US7811231B2 (en)||2002-12-31||2010-10-12||Abbott Diabetes Care Inc.||Continuous glucose monitoring system and methods of use|
|EP1502957B1 (en) *||2003-07-11||2008-08-27||F. Hoffmann-La Roche Ag||Castable diffusion membrane for enzyme-based sensor application|
|CA2473069C (en)||2003-07-11||2014-03-18||F. Hoffmann-La Roche Ag||Castable diffusion membrane for enzyme-based sensor application|
|US8886273B2 (en)||2003-08-01||2014-11-11||Dexcom, Inc.||Analyte sensor|
|US7778680B2 (en)||2003-08-01||2010-08-17||Dexcom, Inc.||System and methods for processing analyte sensor data|
|US8761856B2 (en)||2003-08-01||2014-06-24||Dexcom, Inc.||System and methods for processing analyte sensor data|
|US8275437B2 (en)||2003-08-01||2012-09-25||Dexcom, Inc.||Transcutaneous analyte sensor|
|US7774145B2 (en)||2003-08-01||2010-08-10||Dexcom, Inc.||Transcutaneous analyte sensor|
|US8010174B2 (en)||2003-08-22||2011-08-30||Dexcom, Inc.||Systems and methods for replacing signal artifacts in a glucose sensor data stream|
|US9247901B2 (en)||2003-08-22||2016-02-02||Dexcom, Inc.||Systems and methods for replacing signal artifacts in a glucose sensor data stream|
|CA2541616A1 (en)||2003-09-30||2005-04-14||Andre Mang||Sensor with increased biocompatibility|
|US7519408B2 (en)||2003-11-19||2009-04-14||Dexcom, Inc.||Integrated receiver for continuous analyte sensor|
|EP1711791B1 (en)||2003-12-09||2014-10-15||DexCom, Inc.||Signal processing for continuous analyte sensor|
|US7591801B2 (en)||2004-02-26||2009-09-22||Dexcom, Inc.||Integrated delivery device for continuous glucose sensor|
|US8515516B2 (en)||2004-07-13||2013-08-20||Dexcom, Inc.||Transcutaneous analyte sensor|
|US20060270922A1 (en)||2004-07-13||2006-11-30||Brauker James H||Analyte sensor|
|WO2006090873A1 (en) *||2005-02-25||2006-08-31||Ultizyme International Ltd.||Fuel cell-type enzyme sensor|
|US7920906B2 (en)||2005-03-10||2011-04-05||Dexcom, Inc.||System and methods for processing analyte sensor data for sensor calibration|
|US8744546B2 (en)||2005-05-05||2014-06-03||Dexcom, Inc.||Cellulosic-based resistance domain for an analyte sensor|
|US8364231B2 (en)||2006-10-04||2013-01-29||Dexcom, Inc.||Analyte sensor|
|EP2152350A4 (en)||2007-06-08||2013-03-27||Dexcom Inc||Integrated medicament delivery device for use with continuous analyte sensor|
|JP5212982B2 (en) *||2008-11-06||2013-06-19||独立行政法人物質・材料研究機構||Electrochemical measuring device electrode and the electrode for a biosensor|
|WO2010111660A1 (en)||2009-03-27||2010-09-30||Dexcom, Inc.||Methods and systems for promoting glucose management|
|US9357951B2 (en)||2009-09-30||2016-06-07||Dexcom, Inc.||Transcutaneous analyte sensor|
Family Cites Families (15)
|Publication number||Priority date||Publication date||Assignee||Title|
|US4650547A (en)||1983-05-19||1987-03-17||The Regents Of The University Of California||Method and membrane applicable to implantable sensor|
|EP0284518B1 (en) *||1987-03-27||1992-10-07||Isao Karube||Miniaturized oxygen electrode and miniaturized biosensor and production process thereof|
|US5431160A (en)||1989-07-19||1995-07-11||University Of New Mexico||Miniature implantable refillable glucose sensor and material therefor|
|US5165407A (en)||1990-04-19||1992-11-24||The University Of Kansas||Implantable glucose sensor|
|US5593852A (en)||1993-12-02||1997-01-14||Heller; Adam||Subcutaneous glucose electrode|
|US5773270A (en) *||1991-03-12||1998-06-30||Chiron Diagnostics Corporation||Three-layered membrane for use in an electrochemical sensor system|
|US5387327A (en)||1992-10-19||1995-02-07||Duquesne University Of The Holy Ghost||Implantable non-enzymatic electrochemical glucose sensor|
|ZA9308555B (en)||1992-11-23||1994-08-02||Lilly Co Eli||Technique to improve the performance of electrochemical sensors|
|GB9304306D0 (en)||1993-03-03||1993-04-21||Univ Alberta||Glucose sensor|
|DE4427921C2 (en) *||1994-08-06||2002-09-26||Forschungszentrum Juelich Gmbh||Chemical sensors, in particular biosensors, based on silicon|
|US5711861A (en)||1995-11-22||1998-01-27||Ward; W. Kenneth||Device for monitoring changes in analyte concentration|
|WO1998013685A1 (en)||1996-09-26||1998-04-02||Minimed, Inc.||Silicon-containing biocompatible membranes|
|US5786439A (en)||1996-10-24||1998-07-28||Minimed Inc.||Hydrophilic, swellable coatings for biosensors|
|US6001067A (en) *||1997-03-04||1999-12-14||Shults; Mark C.||Device and method for determining analyte levels|
|US5997817A (en)||1997-12-05||1999-12-07||Roche Diagnostics Corporation||Electrochemical biosensor test strip|
- 2001-03-16 EP EP20010933715 patent/EP1304952A2/en not_active Withdrawn
- 2001-03-16 AU AU6013001A patent/AU6013001A/en active Pending
- 2001-03-16 JP JP2001568055A patent/JP2003527599A/en active Pending
- 2001-03-16 WO PCT/EP2001/003026 patent/WO2001069222A2/en active Application Filing
- 2001-03-16 CA CA 2406814 patent/CA2406814A1/en not_active Abandoned
Non-Patent Citations (1)
|See references of WO0169222A2 *|
Also Published As
|Publication number||Publication date|
|Urban et al.||Miniaturized multi-enzyme biosensors integrated with pH sensors on flexible polymer carriers for in vivo applications|
|EP1497446B1 (en)||Disposable sub-microliter volume sensor with enhanced sample inlet|
|ES2271193T3 (en)||Fluid sampling device and measuring biological analytes.|
|US8298401B2 (en)||Determination of blood glucose in a small volume and in a short test time|
|CA2622503C (en)||Sensor with layered electrodes|
|ES2254368T3 (en)||Electrochemical methods and devices for use in the determination of analyte concentrations hematocrit corrected.|
|EP2283770B1 (en)||Biological fluid constituent sampling and measurement devices and methods|
|US4919767A (en)||Sensor and method for analyte determination|
|US6638772B1 (en)||Electrochemical test device|
|CN1222774C (en)||Electrochemical test strip cards that include an integral dessicant|
|CA2485650C (en)||Biosenser having electrode for determining the rate of flow of a fluid|
|US6849168B2 (en)||Electrochemical microsensor package|
|EP2157907B1 (en)||Electrochemical biosensors and arrays|
|US8180423B2 (en)||Sensor with increased biocompatibility|
|US7547383B2 (en)||Biosensor and method|
|US5696314A (en)||Multilayer enzyme electrode membranes and methods of making same|
|Lambrechts et al.||Biosensors: microelectrochemical devices|
|JP3947356B2 (en)||Microspheres containing the sensor|
|Mullen et al.||Glucose enzyme electrode with extended linearity: Application to undiluted blood measurements|
|US6287451B1 (en)||Disposable sensor and method of making|
|EP0080601B1 (en)||Enzyme electrode membrane, method of making same and polarographic cell structure|
|AK||Designated contracting states:||
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
|17P||Request for examination filed||
Effective date: 20021017
|AX||Extension or validation of the european patent to||
Countries concerned: ALLTLVMKROSI
|17Q||First examination report||
Effective date: 20071029
|18D||Deemed to be withdrawn||
Effective date: 20080509